Regulatory Advancement of ANVISA’s "Custom-Made Device" Specialized Framework
Brazil's health regulatory agency, ANVISA, has established a global benchmark in 2026 for the oversight of 3D-printed medical devices. Recognizing that "one-size-fits-all" regulations do not apply to patient-specific implants, ANVISA shifted its focus to Software and Material Validation.
Under this framework, hospitals operating 3D printing labs are treated as "mini-manufacturers." The regulation ensures that the medical-grade titanium powder or PEEK filaments used have a "Digital Birth Certificate" tracking their purity. Furthermore, the software used to convert CT scans into 3D models must pass rigorous accuracy audits. This regulatory clarity has encouraged massive private investment in 3D printing infrastructure across the Southern Cone, as hospitals now have a clear legal pathway to implement these technologies.